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Diabetic retinopathy (DR) is one of the major complications of Diabetes mellitus. It is 
characterized by retinal microvascular changes caused by chronic exposure to 
hyperglycemia, leading to low tissue oxygenation and ultimately to neovascularization. Laser 
photocoagulation and vitrectomy are the most efficient treatments for DR, but display severe 
side effects such as the destruction of the healthy retina. Another clinical approach uses 
anti-angiogenic agents to prevent and delay progression of neovascularization, but these 
require recurrent local administrations which increase the possibility of retinal detachment, 
vitreous hemorrhage, and cataract formation. 
Studies in human diabetic retinas have revealed an imbalance between pro-angiogenic 
factors such as the vascular endothelial growth factor (VEGF) and anti-angiogenic factors, 
like pigment epithelial-derived factor (PEDF). This imbalance favors pathological 
angiogenesis contributing to DR, and can constitute a therapeutic target. Gene therapy was 
recently shown to be an adequate intervention for long-term treatment of several retinal 
pathologies. We have previously shown the newly engineered episomal vector pEPito to be 
able of sustained gene expression in the mouse retina. We here show that pEPito was able 
to overexpress PEDF for up to three months, both in in vitro cultures of human RPE cells, as 
well as in the retina of diabetic mice after a single subretinal injection. In vivo, in parallel with 
the increase in PEDF we observed a decrease in VEGF levels in injected compared with 
non-injected eyes and a significant effect on two hallmarks of DR: reduction of glucose 
transport (by glucose transporter GLUT1), and reduction of inflammation by decreased 
reactivity of microglia. Jointly, these results point to a significant therapeutic potential of gene 
therapy with pEPito-PEDF for the treatment of DR. 
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Diabetes mellitus (DM) is a group of metabolic diseases characterized by high blood glucose 
that leads to several complications, including diabetic retinopathy (DR). DR is a progressive 
disease that features microvascular dysfunction due to chronic exposure to hyperglycemia.1 
Hyperglycemia is associated with a wide-range of biochemical events that contribute for the 
progression of the disease, such as accumulation of sorbitol, advanced glycation end-
products (AGE), oxidative stress, protein kinase C activation, inflammation, up-regulation of 
the renin-angiotensin system and vascular endothelial growth factor (VEGF).1 Altogether, 
these mechanisms contribute to physiological changes in the retina, including capillary 
basement membrane thickening that induces pericyte and endothelial cell death, causing 
inner blood retinal barrier (BRB) breakdown. This loss of retinal capillary function leads to 
vascular wall leakage, inflammation and ischemia, contributing to retinal neovascularization, 
formation of microaneurysms, edema, and hemorrhages, which lead to irreversible 
blindness.1-3 
Attempts to revert pathological neovascularization have focused on the inhibition of VEGF, 
since the increase in its levels causes changes in the BRB, resulting in retinal macular 
edema and neovascularization.3 However, altered VEGF levels are not the single event 
associated with neovascularization: during DR, the balance between pro- and anti-
angiogenic factors that inhibits pathological angiogenesis.is disrupted. This is caused by an 
up-regulation of angiogenic VEGF and down-regulation of the anti-angiogenic and 
neurotrophic factor pigment epithelial-derived factor (PEDF), secreted by retinal pigment 
epithelial (RPE) cells.4, 5 PEDF has been shown to reduce neovascularization when 
administered as a protein to a mouse model of neovascularization.6, 7 
Common treatments for DR are laser photocoagulation and vitrectomy; they can however 
cause retinal damage and permanent impaired vision, with the success of the treatment 
highly influenced by the disease progression stage.8  Recently, anti-VEGF agents, such as 
pegaptanib, ranibizumab and bevacizumab, have been shown to be more effective inhibiting 





























































































































































NV than surgical approaches. The major disadvantage of these agents is their short half-life, 
which requires repeated intravitreal injections in order to obtain a sustained therapeutic 
effect.5, 9-11 To achieve a sustained therapeutic effect, one can turn to gene therapy, which 
has already been tested as a treatment for several retinal pathologies, 12-14 including ocular 
neovascularization.15 Viral vectors, with overall limitations such limited size of the inserted 
gene, immune response, toxicity, and possible oncogenicity, are widely used for gene 
therapy. Alternative approaches encompass both non-viral vehicles and expression systems 
that can efficiently deliver and provide sustained gene expression. We have previously 
described the effectiveness of the self-replicating episomal vector, pEPito, in long-term gene 
expression in the mouse retina.16 Based on this study, we have used pEPito as an 
expression vector for PEDF to assess its potential for treatment of diabetic retinopathy. 
Using a two-fold approach - in vitro using human RPE cells and in vivo, using the Ins2Akita 
mouse model of DR – we aimed to determine if PEDF can constitute a therapeutic 
alternative for diabetic retinopathy. 
  





























































































































































Materials and Methods 
 
Vector construction 
pEPito-hCMV-eGFP-IRES-IB containing the human CMV enhancer/human elongation factor 
1 alpha promoter was used as backbone, as described before.16, 17 Human PEDF was 
amplified with specific primers containing Nhe I (5’) and Bgl II (3’) restriction sites. The 
amplified fragment was digested with Nhe I and Bgl II and cloned in the pEPito-hCMV, 
digested with the same enzymes. The resulting construct was confirmed by restriction 
enzyme digestion and sequencing. The new plasmid pEPito-hCMV-PEDF with a 6.2 kb size 
was propagated in E. coli GT115. 
 
Evaluation of PEDF expression driven by the pEPito vector in vitro 
Human retinal pigment epithelial (RPE) cell line D407, used in the in vitro experiments, was 
kindly provided by Dr. Jean Bennett from the University of Pennsylvania (USA). Cells were 
kept in culture at 37 ºC in a humid chamber with 5% CO2 and were grown in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, USA) supplemented with 1% 
Penicillin/Streptomycin (Sigma-Aldrich), 1% glutamine (Sigma-Aldrich) and 5% foetal bovine 
serum (Sigma-Aldrich). Culture medium was changed every 2 days. 
Transfection was performed using FuGENE® HD (Promega) with a 3:1 (µL of FuGENE® 
HD:µg of DNA) ratio, according to the manufacturer’s instructions. Briefly, 2x105 cells were 
seeded in a 6-well tissue culture plate (Orange Scientific) and 24h after seeding, cells were 
transfected with 1 µg of DNA. 24 h post transfection cells were transferred from the 6-well 
tissue culture plate to 6 cm Petri dishes. Once a week, for up to three months, the cells were 




Evaluation of PEDF expression driven by the pEPito vector in vivo 





























































































































































Four-month old Ins2Akita (diabetic) mice (The Jackson Laboratory) housed under controlled 
temperature and a 12 h light/dark cycle with food and water ad libitum were used for the in 
vivo experiments. Diabetic phenotype was confirmed 2-months after birth by measuring 
blood glucose levels from a tail puncture (Freestyle Precision, Abbot), with animals used in 
this study exhibiting blood glucose ≥ 500 mg/dl. All experimental procedures were carried 
out according to the Portuguese and European Laboratory Animal Science Association 
(FELASA) Guide for the Care and Use of Laboratory Animals, the European Union Council 
Directive 2010/63/EU for the use of animals in research and the Association for Research in 
Vision and Ophthalmology (ARVO) for the use of animals in ophthalmic and vision research. 
Mice were profoundly anesthetized by intraperitoneal injection of Avertin®. 1uL of DNA (1 
ug/uL) was injected in the subretinal space of the left eye by using an automatic pump 
injector (WPI) and electroporated using 7 mm tweezer electrodes (tweezertodes, Harvard 
Apparatus) connected to a BTX ECM 830 (Harvard Apparatus), as previously described.18 
At 3-months post injection the animals were humanely sacrificed by cervical dislocation, the 
eyes enucleated, and processed depending on the experiment.  
 
Immunofluorescence for PEDF expression in vivo 
For immunohistochemistry, eyes were fixed with ice-cold 4% paraformaldehyde (4% PFA) in 
PBS overnight at 4 ºC, cryoprotected in 30% sucrose in PBS and embedded in OCT 
mounting medium (Tissue-Tek). Immunohistochemistry was performed either in 10 µm thick 
serial sections or whole retinas. Briefly, the samples were washed in 0.1% Triton X100/PBS 
and blocked in 1% goat serum/PBS at room temperature for 1h. Incubation with the primary 
antibodies - rabbit polyclonal anti-PEDF 1:100; (Merck Millipore) and rabbit polyclonal anti-
Iba1 (1:500; Wako) - was performed overnight at 4ºC. 
After incubation samples were washed 3 times in 0.1% Triton X100/PBS, and incubated with 
the secondary antibody (Alexa Fluor® 594; 1:500; Life Technologies, USA) at room 
temperature for 1 h. After 3 washes, slides were mounted with Fluoromount G 
(SouthernBiotech, USA) containing 4',6'-diamidino-2-phenylindole (DAPI). Images were 





























































































































































obtained using an AxioVision microscope, using appropriate filter sets (Axio Observer Z2, 
Zeiss).  
 
PEDF expression by Western blot analysis 
Since PEDF is a secreted protein and PEDF-pEPito administration was performed 
subretinally, we evaluated its expression by Western blot in whole retinas and RPE cells. 
The latter were isolated by dissection of the eyeball and homogenized in ice-cold RIPA 
buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, and 1 
mM EDTA) containing a protease inhibitor cocktail (Roche, Germany).  
Whole protein extract of D407 cells was also prepared using cold RIPA buffer supplemented 
with protease inhibitor cocktail. Protein content was measured by the Bradford assay and 
samples stored at -80 ºC. Thirty micrograms of protein extract were separated in a 
denaturing 12% SDS–PAGE gel, the proteins transferred to a PVDF membrane (Amersham, 
UK), and blocked using Superblock Blocking buffer (Thermo Scientific) containing 0.1% of 
Tween-20 (Sigma-Aldrich, USA) for 1h at room temperature. The primary antibodies used 
were rabbit polyclonal anti-PEDF (1:1000; Merck Millipore), rabbit polyclonal anti-VEGF 
(1:1000; Abcam), rabbit polyclonal anti-GLUT1 (1:3000; Abcam), goat polyclonal anti-Iba1 
(1:1000; Sigma-Aldrich), and rabbit polyclonal anti-GFAP (1:1000; Abcam), and were 
incubated overnight at 4 ºC. β-Actin was incubated for 1h at room temperature (1:10000; 
Sigma-Aldrich). The membrane was probed with an HRP-conjugated secondary antibody for 
1 h at room temperature and the immunoreactive bands were detected by 
chemiluminescence, using an ECL Plus kit (Amersham). 
Secreted PEDF was isolated from the culture medium by protein precipitation using 4 
volumes of ice-cold acetone for 1h, at -20ºC. After precipitation samples were centrifuged for 
10 minutes at 13 000g, the supernatant decanted, and the pellet air-dried for 30 minutes at 
room temperature. The pellet containing precipitated proteins was then re-suspended in 1x 
sample buffer and analyzed by Western blot. 
 





























































































































































Statistical analysis  
All experiments were performed in triplicate and the results expressed as mean ± standard 
error of the mean (SEM). Statistical analysis was performed with GraphPad Prism software. 
A value of P<0.05 was considered to be statistically significant.  































































































































































Characterization of PEDF in the retina of Ins2Akita diabetic mice 
Clinical studies have demonstrated a negative correlation between PEDF levels and the 
development of proliferative diabetic retinopathy.19 To establish if Ins2Akita diabetic mice 
mimic what was observed in humans and are a valid animal model to evaluate PEDF effects, 
PEDF expression was evaluated in the retina of 4-month old Ins2Akita diabetic and compared 
to age-matched wild-type mice. As can be observed in figures 1A and B, there is a 
significantly decrease in PEDF expression in the retina of diabetic animals compared with 
wild-type ones, similar to what is observed in humans. This decrease is much more evident 
in the retinal pigment epithelium (RPE) of diabetic mice (1C and D), compared with 
expression in the neural retina. 
 
 
pEPito enables long-term expression of PEDF in mitotic RPE cells 
For an efficient gene therapy strategy, the expression vector should be able of long-term and 
sustained levels of transgene expression. In our previous study we have described the 
effectiveness of the pEPito episomal vectors in sustained gene expression in retinal cells.16 
We have also shown that plasmids containing the humanized CMV promoter (hCMV), known 
to be less affected by epigenetic silencing effects, were more efficient in promoting gene 
expression in retinal cells both in vitro and in vivo.16 Based on these results, we have chosen 
the pEPito-hCMV backbone to clone PEDF. We have found that our new construct was able 
to overexpress PEDF for almost three months in actively dividing human RPE cells (figure 
2).  
 
Restoration of PEDF protein levels in the retina of Ins2Akita mice 
Subretinal injection of a 1 µL solution of pEPito-hCMV-PEDF was performed into one eye of 
4-month old Ins2Akita mice, with the contralateral eye remaining non-injected, as a control. 





























































































































































Immediately after injection the eyes were electroporated to facilitate entry of the expression 
vector into the cell.18 After the procedure and until sacrifice of the animal, the injected eyes 
had a normal appearance and absence of inflammation, similar to the non-injected, 
contralateral eye. 
The effect of PEDF overexpression was evaluated in the retina of the Ins2Akita diabetic 
mouse, a model of DR. Three months post injection, PEDF expression was analyzed in 10 
micron eye sections, and immunohistochemistry shows an increase in PEDF detected in the 
injected eye, when compared with the contralateral non-injected one. Moreover, the intensity 
of PEDF expression was comparable to one observed in the WT mice (figure 3).  
 
These results were confirmed by Western blot, with an increase in PEDF expression in 
injected compared with non-injected eyes. Moreover, the overexpression of PEDF in the 
retina of Ins2Akita diabetic mice was also associated with a decrease in other hallmarks of 
diabetic retinopathy, such as GFAP, VEGF and glucose transporter 1 (GLUT1) in the retina. 
The last two were also reduced in the RPE of the injected animals, as observed in figure 4. 
One of the features observed in the Ins2Akita diabetic mouse is the activation of microglia 
evidenced by retracted and swollen projections,20 which correlates with inflammation in the 
retina. To analyze for microglia activation as a marker of inflammation, we have performed 
immunohistochemistry for Iba1 (ionized calcium-binding adaptor molecule, figure 5), specific 
for microglia and macrophages.20 When compared with injected retinas (panel B), the 
microglia of non-injected retinas (panel A) has more retracted and swollen projections, a 
feature of reactive morphology of microglia. Iba1 expression is decreased in the injected 
eyes (panel D) when compared with non-injected (panel C), indicating that overexpression of 
PEDF has anti-inflammatory properties. 






























































































































































Diabetic Retinopathy is a severely handicapping disease that affects 90% of type 1 DM 
patients and 60% of type 2 DM patients,21 and the leading cause of blindness in developed 
countries. Neovascularization has been associated with an imbalance between VEGF and 
PEDF.5 Targeting this imbalance can constitute an innovative therapeutic approach, but to 
be an effective therapeutic strategy this balance should be restored in the long-term, and 
gene therapy can achieve long-term expression. Our group has recently shown the 
effectiveness of episomal pEPito expression systems in long-term transgene expression in 
the mouse retina.16 Based on these previous results in this study we have cloned the PEDF 
gene into the pEPito-hCMV backbone and tested this vector both in vitro in human RPE 
cells, and in vivo in the Ins2Akita mouse. The Ins2Akita mouse is a spontaneous non-obese 
model of type 1 diabetes used to study DR.22-24 In these animals retinal complications 
including vascular leakage, loss of pericytes, inflammation, thickening of the inner retinal 
layers,22 and increase of angiogenic markers are visible approximately 12 weeks after the 
onset of hyperglycemia.24 
To test the therapeutic potential of our approach, it was necessary to assess if the PEDF 
expression profile in diabetic Ins2Akita mice reproduces what is observed in humans. Our 
results show a significant decrease in PEDF expression levels in the inner retina of the 
Ins2Akita mice compared with age-matched WT controls (figure 1A-B). This decrease was 
even more pronounced in the RPE of the diabetic mice (Figure 1C-D) showing that the 
secretion of PEDF by the retinal pigment epithelium (RPE) is affected in the early stages of 
the disease. This correlates well to what was described for humans.25, 26 
Our in vitro results show that pEPito was able to overexpress PEDF for up to three months in 
mitotically active RPE cells, proving the mitotic stability of this episomal vector and its long-
term expression. In the Ins2Akita diabetic mouse our expression system was able to express 
PEDF for up to three months. As expected, PEDF overexpression was detected in the RPE 
layer of the retina of injected eyes, where the plasmid was delivered, and in the inner retina 
(figure 3), since PEDF is a secreted protein. Since the eye is an immune-privileged organ, 





























































































































































possessing two distinct blood-retinal barriers that limit the passage of substances between 
the eye and systemic circulation, the leakage of PEDF is not a concern. 
It was previously described that angiogenic VEGF is overexpressed in the retina of 6-month 
old Ins2Akita mice.24 Moreover, it was also described that intravitreal injection of PEDF was 
responsible for down-regulation of VEGF and inhibition of VEGF-VEGFR2 binding in the 
retina of the oxygen-induced retinopathy mouse model.26 Similarly, our results show that 
overexpression of PEDF in the retina of Ins2Akita mice markedly decreases the expression of 
VEGF (figure 4), compared with non-injected eyes, where VEGF levels are higher. 
Recent studies suggest that changes in the microglia, such as increased reactivity, are the 
early feature of DR.25 In Ins2Akita diabetic mice, as early as 8 weeks after the onset of 
hyperglycemia22 there is an increase in the reactivity of retinal microglia, a feature of the 
inflammatory status of the retina. 25 After injection of the pEPito-hCMV-PEDF we have found 
that overexpression of PEDF strongly reduces microglia activity, visualized by the 
nonreactive morphology of microglia. In contrast, in the non-injected eye the reactive 
morphology remained unchanged (figure 5). These results are in accordance with a previous 
study in which topical administration of PEDF peptide (PEDF78-121) in Ins2Akita mice 
prevented microglia activation.7 We have also found a decrease in GFAP expression in the 
injected eye, compared with the non-injected one (figure 4). GFAP expression by astrocytes, 
Müller and glial cells increases after retinal injury such as ischemia, glaucoma,27 and 
diabetes.28 Our results show that treatment with PEDF decreases GFAP expression, which 
can be associated with a reversal in the retinal injury. 
Overall, this study demonstrates the beneficial effect of long-term expression of PEDF in the 
retina of diabetic mice, through the anti-inflammatory and anti-angiogenic potential of PEDF 
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Figure 1: PEDF expression is significantly reduced in the retina of diabetic mice. PEDF 
protein expression was assessed by Western blot of inner retina (A) and RPE (C) tissue 
from diabetic and wild type (WT) mice. B and C represent quantitative data normalized by 
the intensity of β-Actin bands. N=5, *P<0.05 represents significant differences in PEDF 
expression in the retina of Ins2Akita mice compared with the age-matched WT mice, 
determined by the two-tailed t-test. 
 





























































































































































































































































































































Figure 2: Long-term expression of PEDF by D407 cells transfected with pEPito-hCMV-
PEDF. pEPito-hCMV-PEDF was able to overexpress PEDF for up to 77 dpt (days post-
transfection) in mitotically active cells in levels significantly higher than those observed for 
non-transfected cells (NT). 
 
  































































































































































Figure 3: PEDF protein levels are restored after injection of pEPito-hCMV-PEDF. Retinal 
section of an Ins2Akita mouse eye injected with pEPito-hCMV-PEDF-IB three months post 
injection, showing PEDF levels comparable to age-matched WT mice. The contralateral, 
non-injected eye, exhibits a significant reduction in PEDF expression. DAPI (blue) stains 
nuclei and PEDF is marked red. Magnification: 400x 
 
  































































































































































Figure 4: Overexpression of PEDF driven by pEPito-hCMV-PEDF three months post 
subretinal injection in Ins2Akita mice. Expression of several markers relevant for the DR 
phenotype was analyzed in whole retinas and RPE cells. PEDF expression was significantly 
higher in injected animals, while VEGF (angiogenic factor), GLUT1 (responsible for glucose 
uptake to the cell), Iba1 and GFAP (marker of microglia reactivity and indicator of 
inflammation, respectively) show reduction of their levels. Quantification data was obtained 
by normalization with loading control β-Actin bands, followed by a ratio between the 
expression of each marker in the injected eye (I) over the non-injected (NI) one. 
 





























































































































































































































































































































Figure 5: Overexpression of PEDF reduces microglia reactivity in the retina of diabetic mice. 
Whole mount retinas (upper panels, A and B) and section of an Ins2Akita mouse eye (lower 
panels, C and D) staining with Iba1. Panels of pEPito-hCMV-PEDF injected retinas three 
months post injection show migroglia with non-reactive morphology. Non-injected retinas 
display retracted and swollen projections, typical of reactive microglia. DAPI (blue) stains 
nuclei and Iba1 is stained in red. Magnification: 400x 
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